Of tolterodine in subjects with Rolipram ZK 62711 different Ph Genotypes of cytochrome P450 2D6. There is much less variability t 5 HMT in the pharmacokinetics after oral administration of fesoterodine. In contrast to get engaged Ngerter release, where the dose gt betr 4 mg of an approved treatment in the general Bev Lkerung of patients with OAB tolterodine, fesoterodine is both in 4 mg obtained Ltlich and 8 times the t Adjusted doses . In particular, a post hoc analysis of a phase III placebo of fesoterodine, tolterodine ER which is included as a contr The active showed significant gr Ere improvements in episodes of urgency incontinence canceled and the average volume per micturition fesoterodine 8 mg versus tolterodine ER 4 mg. consistent with these results, a placebo controlled EAA last head-to-head study showed that the reduction in UUI episodes after 12 weeks and verst Rkter urination by MVV and 3 rates of diary day were significantly h dry Ago in patients with 8 mg of fesoterodine in patients treated with tolterodine ER 4 mg . Volunteers to sell, the fesoterodine 8 mg was also significantly gr Ere improvements in patient care, perception of bladder condition, urgency Perception Questionnaire and overactive bladder compared with tolterodine ER 4 mg of topics. This study, which is the gr Te controlled Randomized controlled by placebo, is head tohead antimuscarinic study peformed up to date, the second prospective study, the superiority of the maximum available dose of fesoterodine on the maximum available rate tolterodine ER. Remarkably, all were comparisons of endpoints based newspaper, and any public research institutions in this study set, and this is the first study in the placebo group during the time of the superiority of one over the other antimuscarinic controls have been reported. Materials and Methods Study design This was a week randomized, 12 double-blind, double-dummy controlled Controlled by placebo, parallel group study with a 2-week single-blind placebo run in period, conducted at 210 centers in North America, South America, Europe, Asia and Africa between February 2008 and October 2009. F rderf hige subjects were randomized to fesoterodine, tolterodine ER or placebo in a 2 Ratio ratio 1: 2. A randomization scheme with a block size E was set by five Which have since been generated, secure, distributed and stored by Pfizer Global Clinical Data Services. The study was approved by the appropriate institutional review boards and independent Ngigen approved by ethics committees and conducted in accordance with the Protocol, the International Conference on Harmonization Good Clinical Practice guidelines and applicable local regulations and laws. All subjects provided written Einverst Ndniserkl Tion. The U.S. and Europ Ical labels of the products with fesoterodine recommends anf Ngliche dose of fesoterodine 4 mg once t Possible, the 8 mg once t Possible, depending on individual response and reps Possibility is increased Be ht. In this study, all subjects were required especially in the fesoterodine U fesoterodine 4 mg in the first week of 8 mg fesoterodine for the n Chsten 11 weeks followed. All subjects in the tolterodine ER re U tolterodine ER 4 mg every 12 weeks. W During the study, all subjects were asked to take a tablet and a capsule t Was like in the morning. Question M should come Men and women selfrepor